GB Sciences, Inc. (GBLX)
USD 0.0
(-8.0%)
USD 0.0
(-8.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.41 Million USD | 6.01% |
| 2022 | -1.61 Million USD | 15.57% |
| 2021 | -1.79 Million USD | 17.99% |
| 2020 | -2 Million USD | 76.27% |
| 2019 | -5.61 Million USD | 49.86% |
| 2018 | -16.3 Million USD | -6.76% |
| 2017 | -17.17 Million USD | -101.69% |
| 2016 | -8.51 Million USD | -25.59% |
| 2015 | -6.78 Million USD | 14.2% |
| 2014 | -7.9 Million USD | -4112.63% |
| 2013 | -187.62 Thousand USD | -148.78% |
| 2012 | 87.85 Thousand USD | 26.52% |
| 2011 | 49.11 Thousand USD | 59.1% |
| 2010 | -420.06 Thousand USD | 90.48% |
| 2009 | -2.79 Million USD | -2159.91% |
| 2008 | -116.62 Thousand USD | 22.52% |
| 2007 | -150.51 Thousand USD | 35.79% |
| 2006 | -234.4 Thousand USD | 40.2% |
| 2005 | -417.31 Thousand USD | -17.51% |
| 2004 | -333.55 Thousand USD | -370.55% |
| 2003 | -70.88 Thousand USD | 6.11% |
| 2002 | -75.5 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -189.49 Thousand USD | 55.89% |
| 2023 Q3 | -149 Thousand USD | 61.94% |
| 2023 Q4 | -369.89 Thousand USD | -148.24% |
| 2023 FY | - USD | 6.01% |
| 2023 Q2 | -391.49 Thousand USD | -106.59% |
| 2022 Q3 | -386.13 Thousand USD | -51.17% |
| 2022 Q4 | -429.62 Thousand USD | -11.26% |
| 2022 FY | - USD | 15.57% |
| 2022 Q1 | -439.43 Thousand USD | -5.05% |
| 2022 Q2 | -255.43 Thousand USD | 41.87% |
| 2021 Q2 | -384.81 Thousand USD | 19.17% |
| 2021 Q3 | -510.08 Thousand USD | -32.55% |
| 2021 Q4 | -418.29 Thousand USD | 18.0% |
| 2021 FY | - USD | 17.99% |
| 2021 Q1 | -476.05 Thousand USD | 48.31% |
| 2020 FY | - USD | 76.27% |
| 2020 Q1 | -743.46 Thousand USD | 78.51% |
| 2020 Q4 | -921.02 Thousand USD | -246.4% |
| 2020 Q2 | -490.98 Thousand USD | 33.96% |
| 2020 Q3 | -265.88 Thousand USD | 45.85% |
| 2019 Q2 | -2.01 Million USD | -17.93% |
| 2019 FY | - USD | 49.86% |
| 2019 Q1 | -1.71 Million USD | 65.77% |
| 2019 Q3 | -2.2 Million USD | -9.41% |
| 2019 Q4 | -3.45 Million USD | -56.59% |
| 2018 Q4 | -5 Million USD | -72.31% |
| 2018 Q1 | -3.42 Million USD | 46.72% |
| 2018 Q3 | -2.9 Million USD | 58.57% |
| 2018 Q2 | -7 Million USD | -104.43% |
| 2018 FY | - USD | -6.76% |
| 2017 Q3 | -6 Million USD | -147.59% |
| 2017 Q1 | -2.65 Million USD | -24.5% |
| 2017 FY | - USD | -101.69% |
| 2017 Q4 | -6.43 Million USD | -7.15% |
| 2017 Q2 | -2.42 Million USD | 8.59% |
| 2016 FY | - USD | -25.59% |
| 2016 Q4 | -2.13 Million USD | 31.27% |
| 2016 Q2 | -2.1 Million USD | -81.49% |
| 2016 Q1 | -1.16 Million USD | 26.03% |
| 2016 Q3 | -3.1 Million USD | -47.15% |
| 2015 Q2 | -2.64 Million USD | -79.05% |
| 2015 FY | - USD | 14.2% |
| 2015 Q1 | -1.47 Million USD | 62.6% |
| 2015 Q4 | -1.56 Million USD | -44.76% |
| 2015 Q3 | -1.08 Million USD | 59.06% |
| 2014 Q1 | -1.49 Million USD | -1036.86% |
| 2014 Q4 | -3.95 Million USD | -486.62% |
| 2014 FY | - USD | -4112.63% |
| 2014 Q3 | -674.26 Thousand USD | 62.09% |
| 2014 Q2 | -1.77 Million USD | -19.01% |
| 2013 Q3 | -12.8 Thousand USD | 95.94% |
| 2013 Q2 | -315.17 Thousand USD | -971.58% |
| 2013 Q1 | -29.41 Thousand USD | -44.67% |
| 2013 FY | - USD | -148.78% |
| 2013 Q4 | -131.47 Thousand USD | -927.1% |
| 2012 Q1 | -410.75 Thousand USD | -6612.75% |
| 2012 Q4 | -20.33 Thousand USD | -274.13% |
| 2012 FY | - USD | 26.52% |
| 2012 Q2 | -18.04 Thousand USD | 95.61% |
| 2012 Q3 | -5434.00 USD | 69.89% |
| 2011 Q2 | 19.15 Thousand USD | -92.29% |
| 2011 Q3 | -17.94 Thousand USD | -193.72% |
| 2011 Q4 | -6119.00 USD | 65.91% |
| 2011 FY | - USD | 59.1% |
| 2011 Q1 | 248.42 Thousand USD | 1871.92% |
| 2010 Q4 | 12.59 Thousand USD | 112.97% |
| 2010 Q1 | -136.07 Thousand USD | 63.34% |
| 2010 FY | - USD | 90.48% |
| 2010 Q3 | -97.13 Thousand USD | -219.74% |
| 2010 Q2 | -30.38 Thousand USD | 77.67% |
| 2009 Q2 | -1.91 Million USD | -8423.48% |
| 2009 Q3 | -325.83 Thousand USD | 82.99% |
| 2009 Q4 | -371.2 Thousand USD | -13.93% |
| 2009 FY | - USD | -2159.91% |
| 2009 Q1 | -22.47 Thousand USD | 30.97% |
| 2008 Q2 | -19.14 Thousand USD | 61.09% |
| 2008 Q3 | -15.71 Thousand USD | 17.92% |
| 2008 FY | - USD | 22.52% |
| 2008 Q4 | -32.56 Thousand USD | -107.23% |
| 2008 Q1 | -49.2 Thousand USD | -12.69% |
| 2007 Q3 | -31.57 Thousand USD | -279.72% |
| 2007 Q4 | -43.66 Thousand USD | -38.26% |
| 2007 Q2 | 17.57 Thousand USD | 132.97% |
| 2007 Q1 | -53.29 Thousand USD | 73.39% |
| 2007 FY | - USD | 35.79% |
| 2006 Q4 | -200.28 Thousand USD | -444.66% |
| 2006 Q2 | -46.91 Thousand USD | 59.76% |
| 2006 FY | - USD | 40.2% |
| 2006 Q1 | -116.59 Thousand USD | 34.32% |
| 2006 Q3 | 58.11 Thousand USD | 223.86% |
| 2005 Q1 | -80.13 Thousand USD | 3.33% |
| 2005 FY | - USD | -17.51% |
| 2005 Q3 | -72.36 Thousand USD | 16.97% |
| 2005 Q2 | -87.15 Thousand USD | -8.77% |
| 2005 Q4 | -177.51 Thousand USD | -145.31% |
| 2004 Q4 | -82.89 Thousand USD | 51.95% |
| 2004 Q3 | -172.52 Thousand USD | -120.8% |
| 2004 Q1 | -12.5 Thousand USD | 47.02% |
| 2004 Q2 | -78.13 Thousand USD | -525.04% |
| 2004 FY | - USD | -370.55% |
| 2003 Q3 | -13.68 Thousand USD | -3.13% |
| 2003 FY | - USD | 6.11% |
| 2003 Q4 | -23.59 Thousand USD | -72.45% |
| 2003 Q1 | -20.34 Thousand USD | -24.28% |
| 2003 Q2 | -13.26 Thousand USD | 34.78% |
| 2002 Q3 | -29.44 Thousand USD | -113.26% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | -16.36 Thousand USD | 44.4% |
| 2002 Q1 | -15.89 Thousand USD | 0.0% |
| 2002 Q2 | -13.8 Thousand USD | 13.12% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.001% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 76.051% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.786% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 91.826% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.51% |
| Mesoblast Limited | -62.38 Million USD | 97.724% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 7.563% |
| Genus plc | 73.7 Million USD | 101.927% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 78.524% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 59.969% |
| Marizyme, Inc. | -34.28 Million USD | 95.858% |
| ContraFect Corporation | -64.99 Million USD | 97.816% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 83.813% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 68.63% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1.29% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 46.307% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 38.899% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -174.085% |
| Accustem Sciences Inc. | -3.74 Million USD | 62.1% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.056% |
| EV Biologics, Inc. | -1.26 Million USD | -12.055% |
| Q BioMed Inc. | -617.62 Thousand USD | -129.893% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 139.75% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -124.521% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 37.847% |
| Biomind Labs Inc. | -1.03 Million USD | -37.247% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 114.376% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 80.173% |
| Skye Bioscience, Inc. | -13.54 Million USD | 89.519% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 4.54% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -5579.54% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 63.446% |
| IMV Inc. | -35.52 Million USD | 96.003% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.053% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 43.249% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.37% |
| HST Global, Inc. | -5303.00 USD | -26675.127% |
| CSL Limited | 4.78 Billion USD | 100.03% |
| Halberd Corporation | -74.27 Thousand USD | -1811.556% |
| Enzolytics Inc. | -2.12 Million USD | 33.088% |
| Resverlogix Corp. | -11.74 Million USD | 87.908% |
| Affymax, Inc. | -14.29 Million USD | 90.067% |
| SYBLEU INC | -141.57 Thousand USD | -902.949% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 53.644% |
| argenx SE | -216.02 Million USD | 99.343% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.434% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 216.671% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 5.272% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 474.794% |
| AVAX Technologies, Inc. | -6.11 Million USD | 76.771% |
| Zenith Capital Corp. | -8.6 Million USD | 83.501% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.429% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8050.422% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 41.962% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -706.641% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.418% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 50.909% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -35.704% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 21216.672% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 18.864% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 26.083% |
| BioStem Technologies, Inc. | -7.55 Million USD | 81.203% |
| ONE Bio Corp. | 13.61 Million USD | 110.43% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -684.086% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 30.973% |
| Agentix Corp. | -1.37 Million USD | -3.509% |
| LadRx Corporation | 412.28 Thousand USD | 444.396% |
| Cell Source, Inc. | -4.27 Million USD | 66.767% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -286.657% |
| Regen BioPharma, Inc. | 1.46 Million USD | 196.857% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -51.543% |
| NovAccess Global Inc. | -1.03 Million USD | -37.214% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 116.037% |
| Itoco Inc. | -1.86 Million USD | 24.029% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -274.028% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -27.23% |
| Kadimastem Ltd | -2.62 Million USD | 45.896% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -493.722% |
| CytoDyn Inc. | -18.02 Million USD | 92.124% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1696.663% |
| Mobile Lads Corp. | -2.24 Million USD | 36.645% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -11510.802% |
| Qrons Inc. | -40.08 Thousand USD | -3442.539% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -192.351% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 369.207% |
| Rebus Holdings, Inc. | -951 Thousand USD | -49.304% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -33.698% |
| International Stem Cell Corporation | 202 Thousand USD | 802.913% |
| Bioxytran, Inc. | -3.82 Million USD | 62.832% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2597.35% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 42.326% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 96.041% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3055.3% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 48.142% |
| Neutra Corp. | -181.24 Thousand USD | -683.398% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 92.957% |
| PureTech Health plc | -11.62 Million USD | 87.788% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 92.956% |
| IXICO plc | -707 Thousand USD | -100.832% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 81.524% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.063% |
| CSL Limited | 4.73 Billion USD | 100.03% |
| Cellectis S.A. | -92.63 Million USD | 98.467% |